Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.

@article{Juneja2008ContinuingRO,
  title={Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.},
  author={Vinni Juneja and Patricia Keegan and Joseph E. Gootenberg and Mark D. Rothmann and Y. L. Shen and Kyung Yeon Lee and Karen D Weiss and Richard Pazdur},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 11},
  pages={3242-7}
}
PURPOSE Erythropoiesis-stimulating agents (ESA) are approved for the treatment of anemia in patients with nonmyeloid malignancies whose anemia is due to the effect of concomitantly administered chemotherapy. Since the 1993 approval of epoetin alfa in patients with cancer, the risk of thrombovascular events, decreased survival, and poorer tumor control have been increasingly recognized. The risks of ESAs in patients with cancer and the design of trials to assess these risks have been the topic… CONTINUE READING
25 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

- transmitted infections in donations made to Canadian Blood Services

  • CA Sheppard, LE Logdberg, JC Zimring, CD Hillyer
  • 2007

Randomized , double - blind , placebo - controlled trial of erythropoietin in non - small cell lung cancer with disease related anemia

  • GroteT, AL Yeilding, R Castillo
  • JClin Oncol
  • 2007

Efficacy and safety analysis of epoetin alfa in patients with small - cell lung cancer : a randomized , double - blind , placebo - controlled trial

  • B Leyland-Jones
  • JClin Oncol
  • 2005

Similar Papers

Loading similar papers…